3H Health Investment Research
Investment Thesis
3H Health Investment (三正健康投资) is a healthcare-focused venture capital firm founded in 2016 and headquartered across Shanghai and Hong Kong. The firm invests in biotechnology and medical technology companies, partnering with scientists and entrepreneurs to advance therapies for unmet medical needs. The team emphasizes deep science backgrounds, market understanding, and an extensive industry network to identify investment opportunities that create genuine value in healthcare. While rooted in China, the firm describes its vision as global, and its portfolio includes companies headquartered in the US and Singapore alongside its core China book.
Sector Focus
The firm organizes its portfolio into three categories on its own site: Biotech, MedTech, and Others.
- Biotech: antibody and cell/gene therapy companies such as Keymed Biosciences, InnoCare Pharma, CanSino Biologics, HaiHe Pharmaceutical, Rarestone Group, EdiGene, Kanova Biopharma, Therorna (circular RNA), and Alebund Pharmaceuticals (kidney disease).
- MedTech: device and diagnostics companies including Edge Medical Robotics (surgical robotics), SQ Medical, Hemo Bioengineering (neurovascular devices), MicroTech Medical (continuous glucose monitoring), iComfit / Weishi Aikangte (myopia-control eye care devices), Imperative Care (US stroke/vascular devices), CardioFlow Medtech, and Reliablemed (clinical mass spectrometry).
- Others: adjacent healthcare and technology plays such as Tripod GLP (preclinical CRO), JustHealth, and Direct Drive / Benmo Tech (robotics actuator modules), showing willingness to back platform technology adjacent to core healthcare.
Stage Focus
Public financing records show 3H participating primarily at Series B through Series D and growth-stage rounds in its biotech book (e.g., Series C and Series D rounds for Angitia Biopharmaceuticals, a Series A round for the newly formed Timberlyne Therapeutics). Several portfolio companies (Keymed Biosciences, InnoCare Pharma, CanSino Biologics, Edge Medical Robotics) are now publicly listed on the Hong Kong Stock Exchange, indicating the firm carries positions through to IPO rather than exiting early.
Check Size
No specific check-size range is published on the firm's website or in available press coverage. Deal participation in $120M-$180M syndicated rounds suggests meaningful but minority check sizes alongside larger US life-science investors (Bain Capital Life Sciences, OrbiMed, Frazier Life Sciences, Venrock Healthcare Capital Partners).
Lead Tendency
Across the financings reviewed (Angitia Series C and D, Timberlyne Series A), 3H Health Investment consistently appears as a participating existing or new investor rather than the lead — rounds were led or co-led by larger US life-science funds such as Bain Capital Life Sciences, Frazier Life Sciences, Venrock, and Abingworth. The firm's own account of its investment in Edge Medical Robotics (精锋医疗) emphasizes being the company's largest institutional shareholder through five rounds of continued follow-on investment since 2020, suggesting a long-term, conviction-following approach to existing portfolio positions even where it did not originate the round.
Recent Activity
- February 2026: Participated in Angitia Biopharmaceuticals' $130M Series D, co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners.
- January 2026: Edge Medical Robotics (精锋医疗), in which 3H is the largest institutional shareholder, completed its IPO on the Hong Kong Stock Exchange (2675.HK) at HK$43.24/share, opening up more than 38% on debut.
- January 2025: Participated in the $180M Series A launch financing of Timberlyne Therapeutics, a company formed by Mountainfield Venture Partners in partnership with portfolio company Keymed Biosciences to develop CM313 outside Greater China.
- December 2024: Participated in Angitia Biopharmaceuticals' $120M Series C, led by Bain Capital Life Sciences.
- September 2024: Portfolio company Keymed Biosciences received NMPA approval for its IL-4Rα antibody 康悦达® (stapokibart), the first domestically developed antibody of its class approved in China.
Portfolio Highlights
Notable portfolio companies include Keymed Biosciences (HKEX: 02162), InnoCare Pharma, CanSino Biologics (HKEX/SSE-listed), and Edge Medical Robotics (HKEX: 2675, China's first company with approved multi-port, single-port, and bronchoscopic surgical robots). The firm has held its Edge Medical Robotics position since 2020 across five financing rounds through to IPO.
Team
- Shunlong Wang, Ph.D. — Chairman and Founder
- Li Sheng, M.B.A. — Founding Managing Partner
- Minchuan Wang, Ph.D. — Founding Managing Partner
Decision Process
The firm is led by a small founding partnership (a Chairman/Founder plus two Founding Managing Partners), consistent with a partnership-style decision process rather than a solo GP or large investment committee structure.
Founder Preferences
Public commentary from the firm (in its note on the Edge Medical Robotics IPO) emphasizes backing "young, ambitious, hard-working teams," practicing "patient capital," and standing by founders through full industry cycles rather than optimizing for order volume or short-term metrics — framed as a "co-founder"/"entrepreneur's companion" relationship.
Geographic Focus
Primarily Greater China (Shanghai and Hong Kong offices), with selective international co-investments alongside global life-science investors in the US (Timberlyne Therapeutics, Imperative Care) and Singapore (Hemo Bioengineering).